Nucleotides and Alzheimer’s disease: the latest study

Prosol — Mon, 25 Oct 2021 14:06:30 +0000

Nucleotides and Alzheimer’s disease: the latest study

Published on: Oct 25, 2021

In 2019 Prosol announced the promising result of a first study on the role of dietary nucleotides (Ribodiet^®) in Alzheimer disease. Last July a scientific study on the same topic was published on Biomedicine and Pharmacotherapy review; the study showed extremely interesting benefits of RIBODIET® in alleviating memory decline, neuroinflammation and oxidative stress.

Alzheimer’s disease is one of the most common form of dementia, characterized by the deposition of extracellular amyloid-β (Aβ) peptides in the brain. The neuronal death, that characterizes this neurodegenerative disorder, causes irreversible cognitive impairment and behavioral alteration.

The option of natural-derived products and nutraceuticals is scientifically solid and to be considered for a future medical option in industrialized countries. Natural products are not an alternative to drugs but, on the contrary, can be helpful to complement the pharmacological therapy and prevent the onset of chronic diseases.

In this context, has been showed that Ribonucleotides are able to improve the clinical outcomes in immunosuppressive and inflammatory-based diseases.

Scientific investigations on Ribonucleotides for Alzheimer’s disease

A recent study[1] evaluated the effects of a ribonucleotides-based ingredient (Ribodiet^®) in a non-genetic mouse model of AD. Given the strict involvement of nucleosides and nucleotides on neuronal and cognitive functions, the team of the study[2] decided to examine whether a ribonucleotides-based ingredient could ameliorate Aβ‐induced neuro-inflammation and oxidative stress.

Results of the study

The study presented the first and complete overview of how the supplementation with a ribonucleotide-based ingredient (Ribodiet^®) may have a positive impact on synaptic degeneration in Alzheimer Disease and in controlling the most common form of neurodegenerative disease. In particular the study showed that:

Ribodiet^® lessens oxidative stress and brain inflammation
Ribodiet^® modulates amyloid pathology in a murine model of Alzheimer disease
Ribonucleotide-based ingredients are effective on neuro-inflammatory-based disease/s

These results lay the first pillar for a rationale use of ribonucleotide-based ingredients for the treatment of Alzheimer disease and other age-related diseases. The study was published on Biomedicine & Pharmacotherapy. You can view and download full text PDF.

DOWNLOAD FULL TEXT

To learn more about Ribodiet please click here or contact Prosol Spa:
Via Carso, 99 – 24040 MADONE (BG), Italy.
Tel +39 035.99.16.65
E-mail: prosol@prosol.it

[1] Original article – Supplementation with ribonucleotide-based ingredient (Ribodiet®) lessens oxidative stress, brain inflammation, and amyloid pathology in a murine model of Alzheimer on Biomedicine & Pharmacotherapy, Volume 139, July 2021, 111579

[2] Anella Saviano, GianMarco Casillo, Federica Rauccia, Alessia Pernice, Cristina Santarcangelo, Marialuisa Piccolo, MariaGrazia Ferraro, Miriam Ciccone, Alessandro Sgherbini, Nadia Pedretti, Daniele Bonvicini, Carlo Irace, Maria Daglia, Nicola Mascolo, Francesco Maione.

Nucleotides for the control of Alzheimer Disease: Prosol at NTCEurope 2019

Prosol — Wed, 27 Feb 2019 09:51:07 +0000

Nucleotides for the control of Alzheimer Disease: Prosol at NTCEurope 2019

On 27th and 28th of February 2019, Prosol attended the third edition of Nutraceuticals Europe – Summit & Expo. The event, which was held in the Palacio Municipal de Congresos de Madrid, housed over 100 companies of the nutraceutical sector and more than 2300 high-level professionals. As part of NTCEUROPE, Prosol talked at the Seminar Theatre program, the space where companies had the opportunity to share their latest releases and new challenges on nutraceutical products.

With a conference entitled “A natural perspective for the control of Alzheimer Disease”, our Business Development Manager, Alessandro Sgherbini, highlighted the beneficial effects of nucleotides on synaptic degeneration in Alzheimer Disease and in controlling the most common form of neurodegenerative disease. We were pleased with the strong interest in our speech and ingredient solutions and to welcome partners and customers to our booth. We would like to thank Pharmafoods team and all our visitors and we look forward to continuing our dialogue with you!

A natural perspective for the control of Alzheimer Disease

The talk at the Seminar Theatre program of the fair was an opportunity to show the importance of nutraceuticals and nucleotides for the control of Alzheimer Disease.

Alzheimer’s disease is one of the most common form of dementia characterized by the deposition of extracellular amyloid-β (Aβ) peptides in the brain. The neuronal death, that characterizes this neurodegenerative disorder, causes irreversible cognitive impairment and behavioral alteration. Beside synthetic drugs, the use of natural-derived products and/or nutraceuticals could represent a future medical option in industrialized countries. They are not proposed as an alternative to drugs, but instead, can be helpful to complement a pharmacological therapy and prevent the onset of chronic diseases. In this context, nucleotides have demonstrated to improve the clinical outcomes in immunosuppressive and inflammatory-based diseases.

Nucleotides are intracellular compounds involved in many biochemical pathways and nowadays, they are also included in different food supplements formulations targeted to immune system and nervous system. Few years ago, Prosol developed and launched in the market Ribodiet, that is a yeast extract standardized in free nucleotides content (>40%), but also source of AA, Mineral salts and group B vitamins, naturally occurring in the yeast cytoplasm.

A recent study[1] conducted at University of Naples Federico II Naples (Department of Pharmacy, School of Medicine and Surgery), indicated that the ribonucleotide-based formulation of Ribodiet, in a dose dependent manner, is able to revert the state of mnemonic decline and cognitive deficit typical of AD. This study suggests the potential role of Ribodiet as nutraceutical product useful for neurodegenerative disease such as AD, thanks to its anti-inflammatory and neuroprotective effect.

To learn more about Ribodiet please contact us:
Prosol S.p.a, Via Carso, 99 – 24040 MADONE (BG), Italy.
Tel +39 035.99.16.65
Fax +39 035.99.22.46
E-mail: prosol@prosol.it
website. www.prosol.it

[1] Raucci F1, Sgherbini A2, Pedretti N2, Saviano A1, Russo M1, Casillo GM1, Daglia M3 and Maione F1., “Effect of Ribodiet®, a ribonucleotide-based formulation, in a mouse model of Alzheimer’s disease” Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II Naples

Alzheimer Disease – PROSOL

Nucleotides and Alzheimer’s disease: the latest study